The incidence of myopericarditis among adolescents and young adults who received mRNA COVID-19 vaccines is very low, according to a systemic review and meta-analysis published in JAMA Pediatrics.

Although the risk of myopericarditis is no higher with the COVID-19 vaccine than with other vaccines, it may be higher for men and people younger than 30 years.

Myopericarditis is no more likely to occur after receiving a COVID-19 vaccine than it is after getting a flu shot, according to a meta-analysis of studies encompassing more than 400 million ...

The overall risk of myopericarditis following COVID-19 vaccination is very low, affecting 18 people per million vaccine doses. A new study published in The Lancet Respiratory Medicine, confirms ...

The overall risk of myopericarditis following COVID-19 vaccination is very low, affecting 18 people per million vaccine doses. A new study published in The Lancet Respiratory Medicine, confirms ...

Among patients administered a COVID-19 vaccine, myopericarditis risk was higher for those who received an mRNA vaccine (22.6 cases per million doses) compared with a non-mRNA vaccine (7.9 cases ...

Myopericarditis after receiving a dose of a COVID-19 vaccine was also more common in males than in females and in individuals younger than 30 years than those ages 30 and over.

The prognosis for patients with uncomplicated pericarditis, myopericarditis, and perimyocarditis is good, with no evidence of progression to heart failure or mortality. 3,4 There is no clear ...

With COVID-19 vaccines, the risk of myopericarditis was higher for mRNA vaccines (22.6 cases per million doses) than non-mRNA vaccines (7.9 cases per million doses), the investigators found.

The overall risk of myopericarditis—the inflammation of the heart muscle and lining around the heart—following Covid vaccination is low and not significantly different from people receiving ...

Cassimatis and colleagues explain that patients with myopericarditis may be asymptomatic or may report a range of symptoms, including chest pain, fatigue, shortness of breath, palpitations ...

Given her known sulfa allergy and the recent initiation of HCTZ, the patient was diagnosed with HCTZ-induced myopericarditis. The patient was treated with aspirin for symptomatic management and ...